Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Bokemeyer

Showing results (251-260 of 333) with videos related to

Pageof 34
Sort By:
British Journal of Cancer|August 17, 2000
A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancerC Kollmannsberger, D Quietzsch, C Haag, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 8, 2010
Phase I trial of SU14813 in patients with advanced solid malignanciesW Fiedler, G Giaccone, P Lasch, et al.
Investigational New Drugs|April 6, 2006
A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxaneJ A Ajani, H Safran, C Bokemeyer, et al.
ESMO Open|January 9, 2021
Supportive care in patients with cancer during the COVID-19 pandemicM Aapro, G H Lyman, C Bokemeyer, et al.
Anti-Cancer Drugs|June 5, 2002
Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancerF Honecker, C Kollmannsberger, D Quietzsch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1995
Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trialD F Bajorin, C R Nichols, H J Schmoll, et al.
Cancer|July 1, 1993
Single-agent carboplatinum for advanced seminoma. A phase II studyH J Schmoll, A Harstrick, C Bokemeyer, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1993
A pilot study of rapidly alternating epirubicin/dacarbazine and ifosfamide as first-line therapy for metastatic soft-tissue sarcoma in adultsA Harstrick, C Bokemeyer, H J Schmoll, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 1999
First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysisC Bokemeyer, C Kollmannsberger, C Meisner, et al.
Anticancer Research|March 28, 2001
Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamideJ T Hartmann, L M Fels, A Franzke, et al.
Pageof 34

Showing results (251-260 of 333) with videos related to

Sort By:
Pageof 34
British Journal of Cancer|August 17, 2000
A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancerC Kollmannsberger, D Quietzsch, C Haag, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 8, 2010
Phase I trial of SU14813 in patients with advanced solid malignanciesW Fiedler, G Giaccone, P Lasch, et al.
Investigational New Drugs|April 6, 2006
A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxaneJ A Ajani, H Safran, C Bokemeyer, et al.
ESMO Open|January 9, 2021
Supportive care in patients with cancer during the COVID-19 pandemicM Aapro, G H Lyman, C Bokemeyer, et al.
Anti-Cancer Drugs|June 5, 2002
Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancerF Honecker, C Kollmannsberger, D Quietzsch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1995
Recombinant human granulocyte-macrophage colony-stimulating factor as an adjunct to conventional-dose ifosfamide-based chemotherapy for patients with advanced or relapsed germ cell tumors: a randomized trialD F Bajorin, C R Nichols, H J Schmoll, et al.
Cancer|July 1, 1993
Single-agent carboplatinum for advanced seminoma. A phase II studyH J Schmoll, A Harstrick, C Bokemeyer, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1993
A pilot study of rapidly alternating epirubicin/dacarbazine and ifosfamide as first-line therapy for metastatic soft-tissue sarcoma in adultsA Harstrick, C Bokemeyer, H J Schmoll, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 1999
First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysisC Bokemeyer, C Kollmannsberger, C Meisner, et al.
Anticancer Research|March 28, 2001
Comparative study of the acute nephrotoxicity from standard dose cisplatin +/- ifosfamide and high-dose chemotherapy with carboplatin and ifosfamideJ T Hartmann, L M Fels, A Franzke, et al.
Pageof 34